HOME >> MEDICINE >> NEWS
Molecular testing in patients with rare cancer predicts response to Gleevec

PORTLAND, Ore. -- Patients with gastrointestinal stromal tumors (GIST) who have a particular genetic mutation are more likely to respond to Gleevec (imatinib) than those without the mutation, according to OHSU study results showcased at the 2005 annual meeting of the American Society of Clinical Oncology (ASCO). The results confirm previous observations and provide a foundation for molecular testing that can predict who will best respond to treatment with Gleevec.

"Increasingly, there will be more drugs like Gleevec that are very specific in their action, and patients' responses to them will be dictated by their tumor biology," said Michael C. Heinrich, M.D., principal investigator of the study. "Performing molecular tests on patients' tumors will be useful for doctors in determining how patients should be treated."

Heinrich is a professor of medicine (hematology/medical oncology) in the OHSU School of Medicine and the Portland Veteran Affairs Medical Center (PVAMC) and a member of the OHSU Cancer Institute.

Gastrointestinal stromal tumors, which occur in the stomach and intestines, are diagnosed in about 5,000 Americans annually. Surgery is the treatment of choice for localized tumors, but in many patients the tumor recurs and spreads elsewhere, particularly to the liver. Without Gleevec, at this metastatic stage the disease is rapidly fatal because chemotherapy, radiation and surgery are ineffective in advanced cases.

Gleevec works by inhibiting a protein called KIT, which is abnormally expressed in GIST and fuels tumor growth by signaling cancer cells to keep growing. The majority of GIST patients have dramatic clinical improvement in their disease (tumor shrinkage) after beginning treatment with Gleevec. However, more than half of patients develop resistance to the therapy and experience disease progression after about two years.

In a previous study, Heinrich and colleagues identified differences in the clin
'"/>

Contact: Rachel MacKnight
macknigh@ohsu.edu
503-494-8231
Oregon Health & Science University
15-May-2005


Page: 1 2 3

Related medicine news :

1. Elsevier launches Molecular Oncology
2. Molecular marker may help identify pancreatic cancer, and possibly predict survival time
3. Molecular differences between early and advanced melanomas could provide new drug targets
4. Molecular structure reveals how botulinum toxin attaches to nerve cells
5. Molecular medicine comes to the rescue
6. Molecular switch may turn off immune cells that target HIV
7. Molecular imaging may lead to earlier diagnosis of childhood respiratory virus
8. The Molecular Profiling Institute, Inc. and IBM advance technology
9. Molecular Profiling Institute secures $7.5 million in Series B funding
10. Molecular studies in cancer of the colon
11. Molecular ballet unravels, links proteins so cell can direct own movement

Post Your Comments:
*Name:
*Comment:
*Email:


(Date:9/17/2019)... ... September 17, 2019 , ... ... day on Pacifica's Lambert Campus, 249 Lambert Road, Carpinteria, CA. The day ... Clinical Psychology, Counseling Psychology, and Mythological Studies. Program Faculty will host program-specific ...
(Date:9/11/2019)... MEADVILLE, Pa. (PRWEB) , ... September 12, 2019 , ... ... of living with diagnosed coronary artery disease as he hopes to prevent anyone from ... the creation of published author John Saltwick, a writer who was diagnosed with coronary ...
(Date:9/11/2019)... ... September 11, 2019 , ... ... held September 11-14 in Minneapolis at the Mall of America Radisson Blu. Four ... be faculty members for the high-profile, knee-focused conference, which brings together more than ...
(Date:9/11/2019)... ... September 11, 2019 , ... PatientPay, the leading end-to-end ... the issuance of a patent to reduce the level of effort a medical ... and post visit patient statements. , At the core of “Instant Integration for ...
(Date:9/11/2019)... ... September 10, 2019 , ... Women’s ... Hesano is an understanding, caring and highly skilled Obstetrician/Gynecologist. She approaches patients ... Hesano strives to ensure that each visit is comfortable, patient-focused, and that every ...
Breaking Medicine News(10 mins):
(Date:9/14/2019)... (PRWEB) , ... September 14, 2019 , ... ... of four plaintiffs living with peritoneal mesothelioma, a jury in Middlesex County found ... consolidated trial of plaintiffs alleging their mesotheliomas were caused by asbestos-containing J&J talc ...
(Date:9/12/2019)... CITY (PRWEB) , ... September 12, 2019 , ... ... are collaborating to help make the services of CPESN’s clinically integrated network of ... and payers. CPESN USA’s participating pharmacies provide high quality clinical service programs ...
(Date:9/11/2019)... FALLS CHURCH, Va. (PRWEB) , ... September 11, ... ... explosion is revolutionizing image analysis, with many companies developing technologies to evaluate medical ... segments. , Unless one understands the approaches the FDA is taking to AI-based ...
Breaking Medicine Technology:
Cached News: